Sangamo Therapeutics (NASDAQ:SGMO) Issues Earnings Results

Sangamo Therapeutics (NASDAQ:SGMO) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02), Zacks reports. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.70 million.

Sangamo Therapeutics Stock Up 2.9 %

Shares of NASDAQ SGMO opened at $1.01 on Tuesday. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The stock’s 50 day moving average price is $1.10 and its 200-day moving average price is $1.41. The company has a market capitalization of $210.73 million, a PE ratio of -1.35 and a beta of 1.49.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on SGMO shares. Wells Fargo & Company decreased their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Tuesday, December 31st. StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Jefferies Financial Group decreased their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, December 31st. Truist Financial decreased their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Monday, January 27th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Sangamo Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $5.80.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.